MCE - Delayed Quote EUR

Grifols SA (GRF-P.MC)

6.36

-0.04

(-0.62%)

As of 4:11:12 PM GMT+2. Market Open.

Exploring High Growth Tech Stocks In Europe April 2025

In recent weeks, European markets have experienced significant turbulence, with the pan-European STOXX Europe 600 Index dropping 8.44%, marking its steepest decline in five years amid heightened global trade tensions and uncertainty over U.S. tariff policies. As investors navigate this volatile environment, identifying high-growth tech stocks that can withstand economic headwinds becomes crucial; these stocks typically exhibit strong innovation capabilities, robust financial health, and...

Simply Wall St. 16 days ago

GIFLF

GIFOF

GIKLY
High Growth Tech Stocks in Europe for March 2025

As European markets face uncertainty due to U.S. trade policy and recent ECB rate cuts, the pan-European STOXX Europe 600 Index has snapped a 10-week streak of gains, although increased defense and infrastructure spending in Germany and the EU have helped mitigate losses. In this environment, identifying high growth tech stocks involves looking for companies that can leverage innovation to navigate economic challenges and capitalize on shifts in consumer behavior or government spending...

Simply Wall St. last month

GIFLF

GIFOF

GIKLY
Exploring High Growth Tech Stocks In February 2025

As global markets navigate a volatile start to 2025, with the Federal Reserve holding rates steady and AI competition shaking up the tech sector, investors are closely watching how these dynamics impact high-growth opportunities. In this climate of rapid technological advancements and shifting economic indicators, identifying promising tech stocks involves assessing their innovation potential and resilience in adapting to emerging challenges like those posed by new AI developments.

Simply Wall St. 2 months ago

GIFLF

GIFOF

GIKLY
Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson’s Disease

‘Chronos-PD’ is looking for biological signals that could indicate increased chance of developing Parkinson’s disease (PD) years before symptoms appear, leading to new diagnostic tools and disease-modifying therapiesPart of broad Grifols program to find disease-revealing clues in more than 100 million proprietary plasma samples connected to real-world data on thousands of disease states in many therapeutic areasCutting-edge use of AI and proteomics technology paired with real-world evidence unde

GlobeNewswire 3 months ago

GIFLF

GIFOF

GIKLY
Exploring Three High Growth Tech Stocks For Future Potential

As global markets navigate a mixed economic landscape marked by declining consumer confidence and fluctuating indices, technology stocks continue to capture attention with their potential for high growth. In this environment, identifying promising tech stocks involves assessing factors such as innovation, market demand, and the ability to adapt to changing economic conditions.

Simply Wall St. 3 months ago

GIFLF

GIFOF

GIKLY
Exploring High Growth Tech Stocks This December 2024

As global markets reach new heights, with indices like the Russell 2000 hitting record intraday highs, investor sentiment remains buoyed by domestic policy developments and easing geopolitical tensions. In this environment, identifying high-growth tech stocks that can capitalize on current economic trends and technological advancements is crucial for investors seeking to navigate the evolving landscape of December 2024.

Simply Wall St. 4 months ago

GIFLF

GIFOF

GIKLY
GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus

GIGA-2339 contains more than 1,000 fully human recombinant anti-HBV antibodies and is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic HBV infectionSAN CARLOS, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and checkpoint-resistant cancers, and a subsidiary of Grifols, announced today that the first patient has been dosed in a Phas

GlobeNewswire 5 months ago

GIFLF

GIFOF

GIKLY
High Growth Tech Stocks to Watch in November 2024

As global markets react to rising U.S. Treasury yields and a tempered outlook for Federal Reserve rate cuts, small-cap stocks have felt the pressure more acutely than their large-cap counterparts. In this environment, identifying promising high-growth tech stocks involves looking for companies that demonstrate resilience through innovation and adaptability to shifting economic conditions.

Simply Wall St. 5 months ago

GIFLF

GIFOF

GIKLY
Grifols And 2 Other Stocks That Might Be Trading Below Estimated Value

As global markets grapple with rising Treasury yields and tepid economic growth, investors are increasingly focused on identifying stocks that may be trading below their intrinsic value. In this environment, a good stock is often characterized by strong fundamentals and the potential for future growth, making it an attractive option for those seeking value amidst market fluctuations.

Simply Wall St. 5 months ago

GIFLF

GIFOF

GIKLY
Grifols receives FDA approval to treat surgical bleeding with FS solution

Grifols (GRFS) announced that its plasma-protein based fibrin sealant, FS, for controlling surgical bleeding has received approval from the United States Food and Drug Administration, FDA, for pediatric patients. The U.S. indication for children and adolescents extends the availability of FS, which is already approved for this patient segment in Europe, in addition to adults. During surgery Grifols FS promotes hemostasis and tissue sealing, resulting in reduced blood loss and potentially fewer c

TipRanks 5 months ago

GIFLF

GIFOF

GIKLY
Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution

Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to hemostasisGrifols surgical bleeding management treatments form part of an increasingly robust portfolio of innovative therapeutics enhancing the health and well-being of patients BARCELONA, Spain, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medici

GlobeNewswire 5 months ago

GIFLF

GIFOF

GIKLY
Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury

Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from exposure to sulfur mustard, a chemical warfare agent A successful preclinical study of this potentially innovative therapeutic could lead to an FDA license for one of the first medical treatments for sulfur mustard ocular injury Grifols also plans to start a phase 2 clinical trial of an OSIG for dry eye disease in the first half of 2025, part of the com

GlobeNewswire 5 months ago

GIFLF

GIFOF

GIKLY
High Growth Tech Stocks To Watch In October 2024

As global markets react to China's robust stimulus measures, U.S. stocks have reached record highs, buoyed by optimism in technology sectors and AI demand, despite some mixed economic indicators such as consumer confidence and housing data. In this context of heightened market activity and evolving economic conditions, identifying high growth tech stocks involves looking for companies that are well-positioned to capitalize on technological advancements and shifts in consumer behavior driven...

Simply Wall St. 6 months ago

GIFLF

GIFOF

GIKLY
GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat

The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting drug manufacturing and phase 1 trials for the two programs GigaGen’s recombinant polyclonals are part of Grifols’ robust innovation strategy and commitment to delivering the next generation of antibody drugs for patients and healthcare professionals SAN CARLOS, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody

GlobeNewswire 6 months ago

GIFLF

GIFOF

GIKLY
GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339

GIGA-2339 is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic hepatitis B virus (HBV) infection; trial initiation expected in Q4 2024 Containing more than 1,000 fully human recombinant anti-HBV antibodies, GIGA-2339 reproduces the human body’s natural immune response GigaGen’s recombinant polyclonals are part of Grifols’ robust innovation strategy and commitment to delivering the next generation of antibody drugs for patients and healthcare profe

GlobeNewswire 8 months ago

GIFLF

GIFOF

GIKLY
Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients

XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go straight to SCIg without initial intravenous therapy Approval, which also includes biweekly dosing, follows phase 4 study data demonstrating comparable total Ig levels when administering XEMBIFY every two weeks versus weekly The expanded label for XEMBIFY provides added flexibility and convenience for patients with primary humoral immunodeficiencies Incr

GlobeNewswire 8 months ago

GIFLF

GIFOF

GIKLY
Three Stocks Estimated To Be Trading With Intrinsic Discounts Between 35.9% And 49.7%

As global markets exhibit mixed signals with the S&P 500 reaching record highs amid cooling labor markets and easing inflation pressures, investors are navigating a complex landscape. In such an environment, identifying stocks that are trading below their intrinsic value could present opportunities for discerning investors looking to potentially enhance their portfolios.

Simply Wall St. 9 months ago

ANPDF

ANPDY

GIFLF
Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years

Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025 Yimmugo will be distributed by Kedrion in the U.S. as part of a broader Group channel strategy, with Grifols focusing on continued growth of its current portfolio for this market It adds to Grifols’ strong franchise of intravenous and subcutaneous immunoglobulins to meet growing patient demand for these therapeutics Yimmugo will be followed by other prote

GlobeNewswire 9 months ago

GIFLF

GIFOF

GIKLY
Grifols Leads Three Stocks That May Be Priced Below Their Estimated True Value

As global markets exhibit mixed signals with modest gains in the U.S. and challenges in sectors like Chinese real estate, investors are keenly watching for opportunities that might be undervalued. In this environment, identifying stocks such as Grifols that potentially trade below their intrinsic value could offer attractive entry points amidst current market conditions.

Simply Wall St. 9 months ago

GRND

GRND-WS

GIFLF
Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group

With today’s announcement of the transaction completion, Grifols and Haier Group will work together through Shanghai RAAS (SRAAS) to drive synergies that enhance China’s healthcare systemThrough a share purchase agreement Grifols has sold a 20% equity stake in SRAAS to Haier Group for RMB 12.5 billion (approximately EUR 1.6 billion)Grifols and SRAAS extend their exclusive albumin distribution agreement over the next 10 years, and SRAAS has the option to prolong it through 2044Grifols will use al

GlobeNewswire 10 months ago

GIFLF

GIFOF

GIKLY

Performance Overview

Return	GRF-P.MC	IBEX 35... (^IBEX)
YTD	-9.85%	+13.73%
1-Year	+7.61%	+18.98%
3-Year	-38.73%	+51.64%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Grifols SA (GRF-P.MC)

Exploring High Growth Tech Stocks In Europe April 2025

High Growth Tech Stocks in Europe for March 2025

Exploring High Growth Tech Stocks In February 2025

Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson’s Disease

Exploring Three High Growth Tech Stocks For Future Potential

Exploring High Growth Tech Stocks This December 2024

GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus

High Growth Tech Stocks to Watch in November 2024

Grifols And 2 Other Stocks That Might Be Trading Below Estimated Value

Grifols receives FDA approval to treat surgical bleeding with FS solution

Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution

Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury

High Growth Tech Stocks To Watch In October 2024

GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat

GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339

Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients

Three Stocks Estimated To Be Trading With Intrinsic Discounts Between 35.9% And 49.7%

Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years

Grifols Leads Three Stocks That May Be Priced Below Their Estimated True Value

Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group

Performance Overview